Physician profile
Linli Xuan
NPI 1609808831
$15,925.36
in general payments reported to CMS, 2019-2025
78 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $725 · 2021: $2,379 · 2022: $3,095 · 2023: $2,856 · 2024: $3,395 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,053 · Long Term Medical Supply Or Device Loan: $1,363 · Education: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,053.20 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $532.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,611.75 | 2019-2025 | |
| Seagen INC. | $1,192.39 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $1,125.74 | 2019-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $875.71 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $844.93 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $659.75 | 2020-2025 | Darzalex, Erleada, Tecvayli |
| Genentech USA, INC. | $641.69 | 2019-2024 | Polivy, Itovebi |
| Abbvie INC. | $537.46 | 2019-2025 | Venclexta |
| Incyte Corporation | $518.66 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Merck Sharp & Dohme LLC | $487.83 | 2020-2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $458.98 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $455.89 | 2020-2023 | Imbruvica, Epkinly |
| Amgen INC. | $408.71 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Lilly USA, LLC | $380.42 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $330.88 | 2021-2025 | Cabometyx |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linli Xuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.